Single Point Partners LLC Purchases New Stake in Danaher Co. (NYSE:DHR)

Single Point Partners LLC purchased a new stake in shares of Danaher Co. (NYSE:DHR) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 936 shares of the conglomerate’s stock, valued at approximately $215,000.

A number of other institutional investors also recently bought and sold shares of DHR. Sovran Advisors LLC purchased a new position in shares of Danaher during the fourth quarter worth $677,000. First Fiduciary Investment Counsel Inc. increased its stake in Danaher by 1.8% during the fourth quarter. First Fiduciary Investment Counsel Inc. now owns 42,796 shares of the conglomerate’s stock worth $9,824,000 after purchasing an additional 741 shares during the period. Pineridge Advisors LLC boosted its stake in shares of Danaher by 63.3% in the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 57 shares during the period. Quilter Plc grew its holdings in shares of Danaher by 4.6% in the fourth quarter. Quilter Plc now owns 62,371 shares of the conglomerate’s stock valued at $14,317,000 after purchasing an additional 2,746 shares in the last quarter. Finally, Elevate Capital Advisors LLC acquired a new stake in Danaher during the 4th quarter worth approximately $829,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Down 1.6 %

Shares of NYSE:DHR opened at $203.42 on Tuesday. Danaher Co. has a 1 year low of $203.00 and a 1 year high of $281.70. The stock has a 50-day simple moving average of $232.72 and a 200-day simple moving average of $251.61. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The stock has a market capitalization of $146.92 billion, a P/E ratio of 38.53, a PEG ratio of 2.68 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the prior year, the firm posted $2.09 EPS. Equities analysts forecast that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.53%. The ex-dividend date was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 11.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

DHR has been the topic of a number of recent research reports. UBS Group cut their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Raymond James reaffirmed a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Barclays decreased their target price on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Wells Fargo & Company dropped their target price on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Finally, KeyCorp upped their target price on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.